, moyenne (±DS) 18-30 ans, n (%) 30-40 ans, n(%) 40-50 ans, n(%) 50-60 ans, n(%) >60 ans, n(%), 0%) Age (années), vol.60

, Lignes directrices pour le dépistage, la prévention et le traitement de l'ostéoporose après greffe de cellules souches hématopoïétiques chez l'adulte selon McClune et al, Annexe, vol.4

, Algorithme de gestion pour les patients subissant une allogreffe de CSH selon l'opinion d'un expert, Annexe, vol.5

. Bibliographie,

M. Audran, P. Insalaco, and E. Legrand, Ostéoporoses secondaires. Définitions et conduite diagnostique, Rev Rhum, vol.68, pp.669-77, 2001.

F. D. Shuler, J. Conjeski, D. Kendall, and J. Salava, Understanding the burden of osteoporosis and use of the World Health Organization FRAX, Orthopedics, vol.35, pp.798-805, 2012.

T. Funck-brentano and O. P. Ostéoporose, EMC -AKOS, vol.2010, pp.1-12

D. Curran, M. Maravic, P. Kiefer, V. Tochon, and P. Fardellone, Epidemiology of osteoporosisrelated fractures in France: a literature review, Joint Bone Spine, vol.77, pp.546-51, 2010.

S. Ferrari, M. L. Bianchi, J. A. Eisman, A. J. Foldes, S. Adami et al., Osteoporosis in young adults: pathophysiology, diagnosis, and management, Osteoporos Int J Establ Result Coop Eur Found Osteoporos Natl Osteoporos Found USA, vol.23, pp.2735-2783, 2012.

K. Briot, C. Roux, T. Thomas, H. Blain, D. Buchon et al., Actualisation 2018 des recommandations françaises du traitement de l'ostéoporose post-ménopausique, Rev Rhum, vol.85, pp.428-468, 2018.

E. Legrand, B. Bouvard, E. Hoppé, and M. Audran, Ostéoporoses : généralités, stratégie diagnostique, EMC -Appar Locomoteur, vol.7, issue.2, pp.1-5, 2012.

J. Desoutter, R. Mentaverri, M. Brazier, and S. Kamel, Le remodelage osseux normal et pathologique, Rev Francoph Lab, vol.2012, pp.33-42, 2012.

K. N. Weilbaecher, Mechanisms of osteoporosis after hematopoietic cell transplantation, Biol Blood Marrow Transplant J Am Soc Blood Marrow Transplant, vol.6, pp.165-74, 2000.

X. Guillot, Les différents types d'ostéoporose et leurs stratégies thérapeutiques, Actual Pharm, vol.54, pp.18-22, 2015.

L. C. Hofbauer and M. Schoppet, Clinical implications of the osteoprotegerin/RANKL/RANK system for bone and vascular diseases, JAMA, vol.292, pp.490-495, 2004.

D. L. Lacey, E. Timms, H. L. Tan, M. J. Kelley, C. R. Dunstan et al., Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation, Cell, vol.93, pp.165-76, 1998.

W. J. Boyle, W. S. Simonet, and D. L. Lacey, Osteoclast differentiation and activation, Nature, vol.423, pp.337-379, 2003.

, Writing Group for the ISCD Position Development Conference. Diagnosis of osteoporosis in men, premenopausal women, and children, J Clin Densitom Off J Int Soc Clin Densitom, vol.7, pp.17-26, 2004.

E. Shevroja, O. Lamy, L. Kohlmeier, F. Koromani, F. Rivadeneira et al., Use of Trabecular Bone Score (TBS) as a Complementary Approach to Dual-energy X-ray Absorptiometry (DXA) for Fracture Risk Assessment in Clinical Practice, J Clin Densitom Off J Int Soc Clin Densitom, vol.20, pp.334-379, 2017.

K. Siminoski, G. Jiang, J. D. Adachi, D. A. Hanley, G. Cline et al., Accuracy of height loss during prospective monitoring for detection of incident vertebral fractures, Osteoporos Int J Establ Result Coop Eur Found Osteoporos Natl Osteoporos Found USA, vol.16, pp.403-413, 2005.

K. Briot, Les apports de la DXA en dehors de la mesure de la densité minérale osseuse, Rev Rhum, vol.80, pp.225-255, 2013.

D. J. Van-der-voort, P. P. Geusens, and G. J. Dinant, Risk factors for osteoporosis related to their outcome: fractures, Osteoporos Int J Establ Result Coop Eur Found Osteoporos Natl Osteoporos Found USA, vol.12, pp.630-638, 2001.

H. Autorité-de-santé, Les médicaments de l'ostéoporose

J. A. Kanis, E. V. Mccloskey, H. Johansson, A. Oden, L. J. Melton et al., A reference standard for the description of osteoporosis, Bone, vol.42, pp.467-75, 2008.

E. M. Lewiecki, C. M. Gordon, S. Baim, M. B. Leonard, N. J. Bishop et al., International Society for Clinical Densitometry 2007 Adult and Pediatric Official Positions, Bone, vol.43, pp.1115-1136, 2008.

K. Briot, Ostéoporose : critères de diagnostic et de suivi. L'outil FRAX®. Scores radiologiques, Rev Rhum Monogr, vol.77, pp.167-72, 2010.

H. Autorité-de-santé, Prise en charge de l'ostéoporose, 2006.

C. Roux and K. Briot, Place actuelle de l'ostéodensitométrie, Rev Rhum, vol.83, pp.264-270, 2016.

G. Couraud, C. Souffir, E. Gaigneux, S. Kolta, C. Roux et al., Adjusting FRAX® on TBS for identification of subjects at high risk of fractures, Bone, vol.101, pp.214-222, 2017.

K. Briot, B. Cortet, C. Roux, L. Fardet, V. Abitbol et al., Actualisation 2014 des recommandations sur la prévention et le traitement de l'ostéoporose cortico-induite, Rev Rhum, vol.81, pp.385-94, 2014.

D. Hans, E. ?te?ová, and O. Lamy, The Trabecular Bone Score (TBS) Complements DXA and the FRAX as a Fracture Risk Assessment Tool in Routine Clinical Practice, Curr Osteoporos Rep, vol.15, pp.521-552, 2017.

W. D. Leslie, E. Shevroja, H. Johansson, E. V. Mccloskey, N. C. Harvey et al., Riskequivalent T-score adjustment for using lumbar spine trabecular bone score (TBS): the Manitoba BMD registry, Osteoporos Int J Establ Result Coop Eur Found Osteoporos Natl Osteoporos Found USA, vol.29, pp.751-759, 2018.

, Tbs in routine clinical practice: proposals of use

N. C. Harvey, C. C. Glüer, N. Binkley, E. V. Mccloskey, M. Brandi et al., Trabecular bone score (TBS) as a new complementary approach for osteoporosis evaluation in clinical practice, Bone, vol.78, pp.216-240, 2015.

F. M. Ulivieri, B. C. Silva, F. Sardanelli, D. Hans, J. P. Bilezikian et al., Utility of the trabecular bone score (TBS) in secondary osteoporosis, Endocrine, vol.47, pp.435-483, 2014.

N. Dhédin and J. Vernant, Allogreffe de cellules souches hématopoïétiques : réalisation et complications, EMC -Hématologie, vol.2010, pp.1-19

É. Forcade, M. Meunier, and M. Carre, Allogreffe de cellules souches hématopoïétiques Partie 1, Hématologie, vol.19, pp.288-96, 2013.

M. Michallet, Allogreffes de cellules souches hématopoïétiques, Transfus Clin Biol, vol.18, pp.235-280, 2011.

R. Duléry, A. Ménard, S. Chantepie, J. El-cheikh, S. François et al., Sequential Conditioning with Thiotepa in T Cell-Replete Hematopoietic Stem Cell Transplantation for the Treatment of Refractory Hematologic Malignancies: Comparison with Matched Related, Haplo-Mismatched, and Unrelated Donors, Biol Blood Marrow Transplant J Am Soc Blood Marrow Transplant, vol.24, pp.1013-1034, 2018.

C. Pautas, Y. Hicheri, and K. Debbache, Place de l'allogreffe de cellules souches hématopoïétiques dans le traitement des hémopathies malignes de l'adulte, Rev Francoph Lab, pp.45-50, 2007.

H. Jouault and F. Beaujean, Cellules souches périphériques: une nouvelle approche des greffes de moelle osseuse, Rev Fr Lab, pp.49-53, 1998.

D. Blaise, S. Nguyen, J. Bay, P. Chevallier, N. Contentin et al., Greffes de cellules souches hématopoïétiques à partir d'un donneur haplo-identique : recommandations de la SFGM-TC (première partie), Pathol Biol, vol.62, pp.180-184, 2014.

S. Nguyen, D. Blaise, J. Bay, P. Chevallier, N. Contentin et al., Greffes de cellules souches hématopoïétiques à partir d'un donneur haploidentique : recommandations de la SFGM-TC (deuxième partie), Pathol Biol, vol.62, pp.185-194, 2014.

A. L. Andréoli, P. De-latour, R. Thépot, S. Socié, and G. , La maladie chronique du greffon contre l'hôte, Hématologie, vol.16, pp.420-429, 2010.

E. Forcade, M. Meunier, and M. Carre, Allogreffe de cellules souches hématopoïétiques Partie 2, Hématologie, vol.19, pp.342-349, 2013.

A. Menard, Maladie de Greffon contre l'hôte (GVH) : clinique, Hématologie, vol.19, pp.28-37, 2013.

L. Magro, E. Forcade, C. Giraud, A. Granata, N. Parquet et al., Prise en charge de la maladie du greffon contre l'hôte chronique : recommandations de la Société francophone de greffe de moelle et de thérapie cellulaire (SFGM-TC), Bull Cancer, vol.104, pp.145-68, 2017.

V. Dubois, M. Alizadeh, J. H. Bourhis, P. Etancelin, O. Farchi et al., Étude du chimérisme après allogreffe de cellules hématopoïétiques : recommandations de la Société francophone de greffe de moelle et de thérapie cellulaire (SFGM-TC), Bull Cancer, vol.104, pp.59-64, 2017.

T. Guillaume, S. Porcheron, F. Audat, N. Bancillon, A. Berceanu et al., Recommandations de la SFGM-TC concernant l'injection prophylactique, préemptive et curative des lymphocytes du donneur (DLI) après allogreffe de cellules souches hématopoïétiques, Pathol Biol, vol.62, pp.193-199, 2014.

C. Kulak, V. Borba, J. Kulak, and M. R. Custódio, Osteoporosis after transplantation, Curr Osteoporos Rep, vol.10, pp.48-55, 2012.

C. Kulak, V. Borba, K. Júnior, J. Campos, D. J. Shane et al., Post-transplantation osteoporosis, Arq Bras Endocrinol Metabol, vol.54, pp.143-152, 2010.

Y. S. Chae, J. G. Kim, J. H. Moon, S. N. Kim, S. J. Lee et al., Pilot study on the use of zoledronic acid to prevent bone loss in allo-SCT recipients, Bone Marrow Transplant, vol.44, pp.35-41, 2009.

C. Schulte and D. W. Beelen, Bone loss following hematopoietic stem cell transplantation: a long-term follow-up, Blood, vol.103, pp.3635-3678, 2004.

P. Anandi, N. A. Jain, X. Tian, C. O. Wu, P. A. Pophali et al., Factors influencing the late phase of recovery after bone mineral density loss in allogeneic stem cell transplantation survivors, Bone Marrow Transplant, vol.51, pp.1101-1107, 2016.

L. Tauchmanovà, A. Colao, G. Lombardi, B. Rotoli, and C. Selleri, Bone loss and its management in long-term survivors from allogeneic stem cell transplantation, J Clin Endocrinol Metab, vol.92, pp.4536-4581, 2007.

N. Buchs, C. Helg, C. Collao, B. Chapuis, D. Slosman et al., Allogeneic bone marrow transplantation is associated with a preferential femoral neck bone loss, Osteoporos Int J Establ Result Coop Eur Found Osteoporos Natl Osteoporos Found USA, vol.12, pp.880-886, 2001.

S. Yao, P. L. Mccarthy, L. M. Dunford, D. M. Roy, K. Brown et al., High prevalence of early-onset osteopenia/osteoporosis after allogeneic stem cell transplantation and improvement after bisphosphonate therapy, Bone Marrow Transplant, vol.41, pp.393-401, 2008.

K. Kerschan-schindl, M. Mitterbauer, W. Füreder, S. Kudlacek, S. Grampp et al., Bone metabolism in patients more than five years after bone marrow transplantation, Bone Marrow Transplant, vol.34, pp.491-497, 2004.

D. L. Kendler, J. J. Body, M. L. Brandi, R. Broady, J. Cannata-andia et al., Bone management in hematologic stem cell transplant recipients, Osteoporos Int J Establ Result Coop Eur Found Osteoporos Natl Osteoporos Found USA, vol.29, pp.2597-610, 2018.

X. N. Pundole, A. G. Barbo, H. Lin, R. E. Champlin, and H. Lu, Increased incidence of fractures in recipients of hematopoietic stem-cell transplantation, J Clin Oncol Off J Am Soc Clin Oncol, vol.33, pp.1364-70, 2015.

B. L. Mcclune and N. S. Majhail, Osteoporosis after stem cell transplantation, Curr Osteoporos Rep, vol.11, pp.305-315, 2013.

L. Song, X. Xie, L. Peng, Y. Peng, and Y. , Mechanism and Treatment Strategy of Osteoporosis after Transplantation, Int J Endocrinol, p.280164, 2015.

M. Kauppila, K. Irjala, P. Koskinen, K. Pulkki, P. Sonninen et al., Bone mineral density after allogeneic bone marrow transplantation, Bone Marrow Transplant, vol.24, pp.885-894, 1999.

R. Pacifici, Osteoimmunology and its implications for transplantation, Am J Transplant Off J Am Soc Transplant Am Soc Transpl Surg, vol.13, pp.2245-54, 2013.

W. Y. Lee, M. I. Kang, E. S. Oh, K. W. Oh, J. H. Han et al., The role of cytokines in the changes in bone turnover following bone marrow transplantation, Osteoporos Int J Establ Result Coop Eur Found Osteoporos Natl Osteoporos Found USA, vol.13, pp.62-70, 2002.

K. H. Baek and M. I. Kang, Biomarkers of bone and mineral metabolism following bone marrow transplantation, Adv Clin Chem, vol.49, pp.99-120, 2009.

K. H. Baek, K. W. Oh, W. Y. Lee, H. J. Tae, E. J. Rhee et al., Changes in the serum sex steroids, IL-7 and RANKL-OPG system after bone marrow transplantation: influences on bone and mineral metabolism, Bone, vol.39, pp.1352-60, 2006.

E. Stein, P. Ebeling, and E. Shane, Post-transplantation osteoporosis, Endocrinol Metab Clin North Am, vol.36, pp.937-963, 2007.

L. Tauchmanovà, B. Serio, D. Puente, A. Risitano, A. M. Esposito et al., Longlasting bone damage detected by dual-energy x-ray absorptiometry, phalangeal osteosonogrammetry, and in vitro growth of marrow stromal cells after allogeneic stem cell transplantation, J Clin Endocrinol Metab, vol.87, pp.5058-65, 2002.

B. L. Mcclune, L. E. Polgreen, L. A. Burmeister, A. H. Blaes, D. A. Mulrooney et al., Screening, prevention and management of osteoporosis and bone loss in adult and pediatric hematopoietic cell transplant recipients, Bone Marrow Transplant, vol.46, pp.1-9, 2011.

A. Lo and R. R. Alloway, Strategies to reduce toxicities and improve outcomes in renal transplant recipients, Pharmacotherapy, vol.22, pp.316-344, 2002.

P. R. Ebeling, Approach to the patient with transplantation-related bone loss, J Clin Endocrinol Metab, vol.94, pp.1483-90, 2009.

A. Banfi, M. Podestà, L. Fazzuoli, M. R. Sertoli, M. Venturini et al., High-dose chemotherapy shows a dose-dependent toxicity to bone marrow osteoprogenitors: a mechanism for post-bone marrow transplantation osteopenia, Cancer, vol.92, pp.2419-2447, 2001.

R. S. Weinstein, Glucocorticoid-Induced Bone Disease, N Engl J Med, vol.365, pp.62-70, 2011.

G. Ayoub and T. Bardin, Complications ostéoarticulaires des transplantations d'organe, EMC -Appar Locomoteur, pp.1-7, 2007.

C. Marcelli and . Ostéoporose-cortisonique, EMC -Appar Locomoteur, vol.2011, pp.1-10

T. P. Van-staa, H. Leufkens, and C. Cooper, The epidemiology of corticosteroid-induced osteoporosis: a meta-analysis, Osteoporos Int J Establ Result Coop Eur Found Osteoporos Natl Osteoporos Found USA, vol.13, pp.777-87, 2002.

J. V. Torregrosa, Immunosuppression and bone loss after transplantation, Transplant Proc, vol.33, pp.3665-3672, 2001.

A. Cohen and E. Shane, Osteoporosis after solid organ and bone marrow transplantation

, Osteoporos Int J Establ Result Coop Eur Found Osteoporos Natl Osteoporos Found USA, vol.14, pp.617-647, 2003.

R. A. Adler, Glucocorticoid-induced osteoporosis: management update, Curr Osteoporos Rep, vol.8, pp.10-14, 2010.

M. J. Välimäki, K. Kinnunen, L. Volin, R. Tähtelä, E. Löyttyniemi et al., A prospective study of bone loss and turnover after allogeneic bone marrow transplantation: effect of calcium supplementation with or without calcitonin, Bone Marrow Transplant, vol.23, pp.355-61, 1999.

L. Tauchmanovà, C. Selleri, M. Esposito, D. Somma, C. Orio et al., Beneficial treatment with risedronate in long-term survivors after allogeneic stem cell transplantation for hematological malignancies, Osteoporos Int J Establ Result Coop Eur Found Osteoporos Natl Osteoporos Found USA, vol.14, pp.1013-1022, 2003.

K. Kananen, L. Volin, K. Laitinen, H. Alfthan, T. Ruutu et al., Prevention of bone loss after allogeneic stem cell transplantation by calcium, vitamin D, and sex hormone replacement with or without pamidronate, J Clin Endocrinol Metab, vol.90, pp.3877-85, 2005.

L. Tauchmanovà, D. Simone, G. Musella, T. Orio, F. Ricci et al., Effects of various antireabsorptive treatments on bone mineral density in hypogonadal young women after allogeneic stem cell transplantation, Bone Marrow Transplant, vol.37, pp.81-89, 2006.

A. P. Grigg, P. Shuttleworth, J. Reynolds, A. P. Schwarer, J. Szer et al., Pamidronate reduces bone loss after allogeneic stem cell transplantation, J Clin Endocrinol Metab, vol.91, pp.3835-3878, 2006.

P. Hari, T. E. Defor, D. H. Vesole, C. N. Bredeson, and L. J. Burns, Intermittent zoledronic Acid prevents bone loss in adults after allogeneic hematopoietic cell transplantation, Biol Blood Marrow Transplant J Am Soc Blood Marrow Transplant, vol.19, pp.1361-1368, 2013.

H. Lu, R. E. Champlin, U. Popat, X. Pundole, C. P. Escalante et al., Ibandronate for the prevention of bone loss after allogeneic stem cell transplantation for hematologic malignancies: a randomized-controlled trial, BoneKEy Rep, vol.5, p.843, 2016.

J. Cornillon, M. Vantyghem, M. A. Couturier, E. De-berranger, S. François et al., Suivi et prise en charge des troubles endocriniens en post-greffe de cellules souches hématopoïétiques : insuffisance corticotrope et ostéoporose, Pathol Biol, vol.61, pp.171-174, 2013.

P. Fardellone and G. Désaméricq, Consommation des traitements antiostéoporotiques et incidence des fractures ostéoporotiques en France entre 2014 et 2016 : une prise en charge médicamenteuse insuffisante, Rev Rhum, vol.86, pp.387-92, 2019.

R. A. Yood, S. E. Andrade, K. M. Mazor, H. Fouayzi, W. Chan et al., Bone density consequences of initiation and compliance with therapy for osteoporosis, Arthritis Care Res, vol.62, pp.1440-1445, 2010.

, Os brisés, vies brisées : une feuille de route pour résoudre la crise des fractures de fragilité en France

K. Huntjens, T. Van-geel, J. Van-den-bergh, S. Van-helden, P. Willems et al., Fracture liaison service: impact on subsequent nonvertebral fracture incidence and mortality, J Bone Joint Surg Am, vol.96, p.29, 2014.

C. Schulte, D. W. Beelen, U. W. Schaefer, and K. Mann, Bone loss in long-term survivors after transplantation of hematopoietic stem cells: a prospective study, Osteoporos Int J Establ Result Coop Eur Found Osteoporos Natl Osteoporos Found USA, vol.11, pp.344-53, 2000.

J. M. Stern, K. M. Sullivan, S. M. Ott, K. Seidel, J. C. Fink et al., Bone density loss after allogeneic hematopoietic stem cell transplantation: a prospective study, Biol Blood Marrow Transplant J Am Soc Blood Marrow Transplant, vol.7, pp.257-64, 2001.

P. R. Ebeling, D. M. Thomas, B. Erbas, J. L. Hopper, J. Szer et al., Mechanisms of bone loss following allogeneic and autologous hemopoietic stem cell transplantation, J Bone Miner Res Off J Am Soc Bone Miner Res, vol.14, pp.342-50, 1999.

W. Lee, K. Baek, E. Rhee, H. Tae, K. Oh et al., Impact of circulating bone-resorbing cytokines on the subsequent bone loss following bone marrow transplantation, Bone Marrow Transplant, vol.34, pp.89-94, 2004.

A. D. Petropoulou, R. Porcher, A. Herr, A. Devergie, T. F. Brentano et al., Prospective assessment of bone turnover and clinical bone diseases after allogeneic hematopoietic stem-cell transplantation, Transplantation, vol.89, pp.1354-61, 2010.

B. Serio, L. Pezzullo, R. Fontana, S. Annunziata, R. Rosamilio et al., Accelerated bone mass senescence after hematopoietic stem cell transplantation, Transl Med UniSa, vol.5, pp.7-13, 2013.

Y. Lim, K. H. Baek, H. Kim, S. Lee, J. W. Lee et al., Changes in trabecular bone score and bone mineral density following allogeneic hematopoietic stem cell transplantation, Bone, vol.124, pp.40-46, 2019.

C. Bardin, Chapitre29 -Leucémies chroniques: Traitement de la leucémie myéloïde chronique, Association nationale des enseignants de pharmacie clinique, pp.247-266, 2016.

S. J. Lee, T. Seaborn, F. J. Mao, S. C. Massey, N. Q. Luu et al., Frequency of abnormal findings detected by comprehensive clinical evaluation at 1 year after allogeneic hematopoietic cell transplantation, Biol Blood Marrow Transplant J Am Soc Blood Marrow Transplant, vol.15, pp.416-436, 2009.

M. A. Paggiosi, N. Peel, and R. Eastell, The impact of glucocorticoid therapy on trabecular bone score in older women, Osteoporos Int J Establ Result Coop Eur Found Osteoporos Natl Osteoporos Found USA, vol.26, pp.1773-80, 2015.

E. S. Leib and R. Winzenrieth, Bone status in glucocorticoid-treated men and women

, Osteoporos Int J Establ Result Coop Eur Found Osteoporos Natl Osteoporos Found USA, vol.27, pp.39-48, 2016.

W. D. Leslie, B. Aubry-rozier, L. M. Lix, S. N. Morin, S. R. Majumdar et al., Spine bone texture assessed by trabecular bone score (TBS) predicts osteoporotic fractures in men: the Manitoba Bone Density Program, Bone, vol.67, pp.10-14, 2014.

E. Leib, R. Winzenrieth, O. Lamy, and D. Hans, Comparing bone microarchitecture by trabecular bone score (TBS) in Caucasian American women with and without osteoporotic fractures, Calcif Tissue Int, vol.95, pp.201-209, 2014.

W. D. Leslie, H. Johansson, J. A. Kanis, O. Lamy, A. Oden et al., Lumbar spine texture enhances 10-year fracture probability assessment, Osteoporos Int J Establ Result Coop Eur Found Osteoporos Natl Osteoporos Found USA, vol.25, pp.2271-2278, 2014.

D. Hans, A. L. Goertzen, M. Krieg, and W. D. Leslie, Bone microarchitecture assessed by TBS predicts osteoporotic fractures independent of bone density: the Manitoba study, J Bone Miner Res Off J Am Soc Bone Miner Res, vol.26, pp.2762-2771, 2011.

T. A. Gooley, J. W. Chien, S. A. Pergam, S. Hingorani, M. L. Sorror et al., Reduced Mortality after Allogeneic Hematopoietic-Cell Transplantation, N Engl J Med, vol.363, pp.2091-101, 2010.

B. N. Savani, T. Donohue, E. Kozanas, A. Shenoy, A. K. Singh et al., Increased risk of bone loss without fracture risk in long-term survivors after allogeneic stem cell transplantation, Biol Blood Marrow Transplant J Am Soc Blood Marrow Transplant, vol.13, pp.517-537, 2007.

J. Lin, H. Chen, C. Yang, C. Lai, H. Lin et al., Risk of osteoporosis and pathologic fractures in cancer patients who underwent hematopoietic stem cell transplantation: a nationwide retrospective cohort study, Oncotarget, vol.8, pp.34811-34820, 2017.

J. Compston, Glucocorticoid-induced osteoporosis: an update, Endocrine, vol.61, pp.7-16, 2018.

X. Pundole, W. A. Murphy, C. C. Ebede, E. Karim, S. Manocha et al., Fracture risk prediction using FRAX in patients following hematopoietic stem cell transplantation, Arch Osteoporos, vol.13, p.38, 2018.

I. R. Dissanayake, G. R. Goodman, A. R. Bowman, Y. Ma, S. Pun et al., Mycophenolate mofetil: a promising new immunosuppressant that does not cause bone loss in the rat, Transplantation, vol.65, pp.275-283, 1998.

G. A. Smallwood, D. Burns, C. G. Fasola, A. C. Steiber, and T. G. Heffron, Relationship between immunosuppression and osteoporosis in an outpatient liver transplant clinic, Transplant Proc, vol.37, pp.1910-1911, 2005.

P. Ahmadpoor, S. Reisi, K. Makhdoomi, A. Ghafari, N. Sepehrvand et al., Osteoporosis and related risk factors in renal transplant recipients, Transplant Proc, vol.41, pp.2820-2822, 2009.

S. Yao, S. L. Smiley, K. West, D. Lamonica, M. Battiwalla et al., Accelerated bone mineral density loss occurs with similar incidence and severity, but with different risk factors, after autologous versus allogeneic hematopoietic cell transplantation, Biol Blood Marrow Transplant J Am Soc Blood Marrow Transplant, vol.16, pp.1130-1137, 2010.

E. Canalis, G. Mazziotti, A. Giustina, and J. P. Bilezikian, Glucocorticoid-induced osteoporosis: pathophysiology and therapy, Osteoporos Int J Establ Result Coop Eur Found Osteoporos Natl Osteoporos Found USA, vol.18, pp.1319-1347, 2007.

X. Pundole, H. I. Cheema, G. S. Petitto, M. A. Lopez-olivo, M. E. Suarez-almazor et al., Prevention and treatment of bone loss and fractures in patients undergoing a hematopoietic stem cell transplant: a systematic review and meta-analysis, Bone Marrow Transplant, vol.52, pp.663-70, 2017.

C. Kulak, V. Borba, K. Júnior, J. Custódio, and M. R. , Bone disease after transplantation: osteoporosis and fractures risk, Arq Bras Endocrinol Metabol, vol.58, pp.484-92, 2014.

A. H. Hautmann, S. Elad, A. Lawitschka, H. Greinix, H. Bertz et al., Metabolic bone diseases in patients after allogeneic hematopoietic stem cell transplantation: report from the Consensus Conference on Clinical Practice in chronic graft-versus-host disease, Transpl Int Off J Eur Soc Organ Transplant, vol.24, pp.867-79, 2011.

B. Mcclune, N. S. Majhail, and M. Flowers, Bone loss and avascular necrosis of bone after hematopoietic cell transplantation, Semin Hematol, vol.49, pp.59-65, 2012.

N. S. Majhail, J. D. Rizzo, S. J. Lee, M. Aljurf, Y. Atsuta et al.,

, Rinsho Ketsueki, vol.55, pp.607-639, 2014.

P. A. Carpenter, C. L. Kitko, S. Elad, M. Flowers, J. C. Gea-banacloche et al., National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: V. The 2014 Ancillary Therapy and Supportive Care Working Group Report, Biol Blood Marrow Transplant J Am Soc Blood Marrow Transplant, vol.21, pp.1167-87, 2015.

C. Kulak, V. Borba, K. Júnior, J. , and S. E. , Transplantation osteoporosis, Arq Bras Endocrinol Amp Metabol, vol.50, pp.783-92, 2006.

M. Guida, M. A. Castaldi, R. Rosamilio, V. Giudice, F. Orio et al., Reproductive issues in patients undergoing Hematopoietic Stem Cell Transplantation: an update, J Ovarian Res, vol.9, p.72, 2016.

L. Tauchmanovà, P. Ricci, B. Serio, G. Lombardi, A. Colao et al., Short-term zoledronic acid treatment increases bone mineral density and marrow clonogenic fibroblast progenitors after allogeneic stem cell transplantation, J Clin Endocrinol Metab, vol.90, pp.627-661, 2005.